Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LGX818 in BRAF V600-mutant Melanoma
NCT01894672Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jul 2013
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of encorafenib in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Jul 2013; status: completed.
02
Drugs
encorafenib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01894672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01894672.